Technology ID
E-249-2013-0

Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy

Linked ID
TAB-2772
Inventors
David Beall (CDC)
Frederick Quinn (CDC)
Kristin Birkness (CDC)
Manon Deslauriers (CDC)
Peter King (CDC)
Lead Inventors
Frederick Quinn (CDC)
Co-Inventors
David Beall (CDC)
Kristin Birkness (CDC)
Manon Deslauriers (CDC)
Peter King (CDC)
Development Stages
Prototype
Development Status
  • In vitro data available
  • Prototype
Research Products
Research Equipment
ICs
CDC
Commercial Applications
  • In vitro modeling system
  • Basic research into tuberculosis-host interactions
  • Drug candidate screening
CDC researchers have developed an in vitro model system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and in vitro candidate-drug screening. The approach incorporates autologous human macrophages, human peripheral blood mononuclear cells, and mycobacteria to mimic in situ granuloma formation in a controllable in vitro environment. This technology would be broadly useful for investigations into the numerous facets of early granuloma host-pathogen interaction, ultimately leading to improved prevention, intervention, and treatment strategies.
Competitive Advantages
  • Low-cost alternative for modeling mycobacterial infections within complex tissue systems
  • Allows researchers to examine early-stage granuloma formation in a highly controllable, human-based modeling system
  • Cost-effective screening of potential therapeutic compounds and/or phenotypically-interesting mycobacteria

Request More Info

Licensing Contact